Clinical trial
THETIS: Non-interventional, Multicenter Clinical Study to Evaluate the Predictive Value of the Heart Failure Questionnaire (HF-Q) for the Occurrence of Μajor Αdverse Cardiovascular Events (MACE) According to New York Heart Association Functional Classification (NYHA) in Patients With Symptomatic Heart Failure
NCT03947853 is registered in ClinicalTrials.gov with Elpen Pharmaceutical Co. Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- THETIS: Non-interventional, Multicenter Clinical Study to Evaluate the Predictive Value of the Heart Failure Questionnaire (HF-Q) for the Occurrence of Μajor Αdverse Cardiovascular Events (MACE) According to New York Heart Association Functional Classification (NYHA) in Patients With Symptomatic Heart Failure
- Lead sponsor
- Elpen Pharmaceutical Co. Inc.
- Phase
- Observational
- Overall status
- Withdrawn
- Start date
- October 1, 2019
- Completion date
- January 31, 2020
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
heart failure, heart failure nyha class ii, heart failure nyha class iii, heart failure nyha class iv